0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Diagnosis of Colorectal Cancer and Adenomatous Polyps of the Colon Based on the Level of MicroRNA Expression in the Mucous Membrane (Pilot Clinical Study)

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The gold standard for colorectal cancer (CRC) diagnosis, colonoscopy with biopsy, is an invasive technique and has some limitations, while the known non-invasive methods do not possess sufficient sensitivity and specificity. The application of microRNA as a diagnostic and prognostic CRC biomarker may compensate for the colonoscopy limitations. However, there are no data in the literature on the existence of real test systems based on the evaluation of microRNA expression. Our pilot study is the first step to creating a test system for CRC diagnosis based on the analysis of microRNA expression in the tissue of the intact colon.

          The aim of the study is to assess the prospects of using the level of microRNA expression as a supplemental method for diagnosing colorectal cancer and adenomatous polyps.

          Materials and Methods

          Patients participating in the study were divided into three groups: group 1 included patients with CRC (n=5), group 2 — patients with polyps in the colon (n=4), and patients without oncological pathology treated for hemorrhoidal disease without exacerbation (n=5) composed group 3.

          Tissue samples of the intact gut were taken from all patients. In groups 1 and 2, biopsy was performed in the process of right-sided laparoscopic resection of the colon with tumor. Samples of the mucous membrane from the distal part of the rectum in patients of group 3 were also collected intraoperatively; they were operated on using Milligan-Morgan technique. In groups 1 and 2, CRC and polyp samples, respectively, were taken for the analysis additionally to the intact gut area.

          The test panel included the following microRNAs: hsa-miR-10b-5p, hsa-miR-20a-5p, hsa-miR-141-3p, hsa-miR-181b-5p. The levels of the reference genes were analyzed with the help of real-time polymerase chain reaction using intercalating SYBR Green stain.

          Results

          Expression of hsa-miR-141-3p in the mucous membrane of the colon in patients of groups 1 and 2 (with CRC and polyps, respectively) was statistically significantly higher than in patients without bowel tumors. At the same time, the expression level of hsa-miR-10b-5p was statistically significantly lower in the tumor tissue (cancer or polyps) in comparison with patients of group 3.

          Lower values of expression in all tested microRNAs have been detected in the CRC tissue relative to the intact mucosa of the same patients. A similar tendency was also observed in patients with adenomatous polyps.

          Conclusion

          The results of the study have shown that of four microRNAs, included into the test panel, hsa-miR-141-3p and hsa-miR-10b-5p were found to have the diagnostic value for identifying tumor colorectal lesions. Thus, our data will assume that supplementing the endoscopic tests of the large intestine by the epigenetic analysis of the mucous membrane is a promising approach to cancer screening procedures.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Multitarget Stool DNA Testing for Colorectal-Cancer Screening

          An accurate, noninvasive test could improve the effectiveness of colorectal-cancer screening. We compared a noninvasive, multitarget stool DNA test with a fecal immunochemical test (FIT) in persons at average risk for colorectal cancer. The DNA test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, and β-actin, plus a hemoglobin immunoassay. Results were generated with the use of a logistic-regression algorithm, with values of 183 or more considered to be positive. FIT values of more than 100 ng of hemoglobin per milliliter of buffer were considered to be positive. Tests were processed independently of colonoscopic findings. Of the 9989 participants who could be evaluated, 65 (0.7%) had colorectal cancer and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile serrated polyps measuring ≥1 cm in the greatest dimension) on colonoscopy. The sensitivity for detecting colorectal cancer was 92.3% with DNA testing and 73.8% with FIT (P=0.002). The sensitivity for detecting advanced precancerous lesions was 42.4% with DNA testing and 23.8% with FIT (P<0.001). The rate of detection of polyps with high-grade dysplasia was 69.2% with DNA testing and 46.2% with FIT (P=0.004); the rates of detection of serrated sessile polyps measuring 1 cm or more were 42.4% and 5.1%, respectively (P<0.001). Specificities with DNA testing and FIT were 86.6% and 94.9%, respectively, among participants with nonadvanced or negative findings (P<0.001) and 89.8% and 96.4%, respectively, among those with negative results on colonoscopy (P<0.001). The numbers of persons who would need to be screened to detect one cancer were 154 with colonoscopy, 166 with DNA testing, and 208 with FIT. In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results. (Funded by Exact Sciences; ClinicalTrials.gov number, NCT01397747.).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN

            Objective Colorectal cancer (CRC) is the third most common cancer worldwide. The geographical and temporal burden of this cancer provides insights into risk factor prevalence and progress in cancer control strategies. We examine the current and future burden of CRC in 185 countries in 2020 and 2040. Methods Data on CRC cases and deaths were extracted from the GLOBOCAN database for the year 2020. Age-standardised incidence and mortality rates were calculated by sex, country, world region and Human Development Index (HDI) for 185 countries. Age-specific rates were also estimated. The predicted number of cases and deaths in 2040 were calculated based on global demographic projections by HDI. Results Over 1.9 million new CRC cases and 930 000 deaths were estimated in 2020. Incidence rates were highest in Australia/ New Zealand and European regions (40.6 per 100 000, males) and lowest in several African regions and Southern Asia (4.4 per 100 000, females). Similar patterns were observed for mortality rates, with the highest observed in Eastern Europe (20.2 per 100 000, males) and the lowest in Southern Asia (2.5 per 100 000, females). The burden of CRC is projected to increase to 3.2 million new cases and 1.6 million deaths by 2040 with most cases predicted to occur in high or very high HDI countries. Conclusions CRC is a highly frequent cancer worldwide, and largely preventable through changes in modifiable risk factors, alongside the detection and removal of precancerous lesions. With increasing rates in transitioning countries and younger adults, there is a pressing need to better understand and act on findings to avert future cases and deaths from the disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Colorectal cancer screening: An updated review of the available options

              Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide. However, colon cancer incidence and mortality is declining over the past decade owing to adoption of effective screening programs. Nevertheless, in some parts of the world, CRC incidence and mortality remain on the rise, likely due to factors including “westernized” diet, lifestyle, and lack of health-care infrastructure and resources. Participation and adherence to different national screening programs remain obstacles limiting the achievement of screening goals. Different modalities are available ranging from stool based tests to radiology and endoscopy with varying sensitivity and specificity. However, the availability of these tests is limited to areas with high economic resources. Recently, FDA approved a blood-based test (Epi procolon®) for CRC screening. This blood based test may serve to increase the participation and adherence rates. Hence, leading to increase in colon cancer detection and prevention. This article will discuss various CRC screening tests with a particular focus on the data regarding the new approved blood test. Finally, we will propose an algorithm for a simple cost-effective CRC screening program.
                Bookmark

                Author and article information

                Journal
                Sovrem Tekhnologii Med
                Sovrem Tekhnologii Med
                stm
                Modern Technologies in Medicine
                Privolzhsky Research Medical University (Russia )
                2076-4243
                2309-995X
                2024
                30 October 2024
                : 16
                : 5
                : 45-51
                Affiliations
                [1]MD, PhD, Surgeon; Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko , 190 Rodionova St., Nizhny Novgorod, 603126, Russia
                [2]MD, PhD, Tutor, Department of General, Operative Surgery and Topographic Anatomy; Privolzhsky Research Medical University , 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia; Surgeon; Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko , 190 Rodionova St., Nizhny Novgorod, 603126, Russia
                [3]MD, DSc, Associate Professor, Chief Researcher, Laboratory of Optical Coherent Tomography, Research Institute of Experimental Oncology and Biomedical Technologies; Privolzhsky Research Medical University , 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia
                [4]MD, DSc, Professor, Department of General, Operative Surgery and Topographic Anatomy; Privolzhsky Research Medical University , 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia
                [5]MD, PhD, Head of the Coloproctology Department; Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko , 190 Rodionova St., Nizhny Novgorod, 603126, Russia
                [6]MD, DSc, Head of the Department of General, Operative Surgery and Topographic Anatomy; Privolzhsky Research Medical University , 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia
                Author notes
                Corresponding author: Maksim V. Bagryantsev, e-mail: maks-bagryancev@ 123456mail.ru

                Conflicts of interest. The authors have no conflicts of interest to declare.

                How to cite: Bagryantsev M.V., Yanyshev A.A., Ryabkov M.G., Abelevich A.I., Dezortsev I.L, Bazayev A.V. Diagnosis of colorectal cancer and adenomatous polyps of the colon based on the level of microrna expression in the mucous membrane (pilot clinical study). Sovremennye tehnologii v medicine 2024; 16(5): 45, https://doi.org/10.17691/stm2024.16.5.05

                Article
                10.17691/stm2024.16.5.05
                11784883
                39897074
                8151ead0-56e8-40cb-b3f9-d75e290ce1a6

                This is an open access article under the CC BY 4.0 license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 23 June 2024
                Funding
                Research funding. The work was financially supported by the funds of the “Priority 2030” grant.
                Categories
                Clinical Supplements

                colorectal cancer,adenomatous polyps,colon mucous membrane,microrna expression

                Comments

                Comment on this article